Bond Screener
Sanofi
LEI 549300E9PC51EN656011, SWIFT SAAVFRPPXXX
Organization name
Sanofi SA
Country name
France
Country of registration
France
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
Public debt
19,248 mln USD
New to Cbonds? · Take a 90-second tour of the platform.
Discover what you can do with Cbonds
Everything you need for fixed income research and monitoring.
- 00:23 Coverage
- 00:40 Bond screener
- 00:54 Parameters
- 01:10 Watchlist, Mobile app
- 01:15 Excel Add-in
Trading Schedule Issuer map
Quotes
/
/
/
pcs.
pcs.
pcs.
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Quotes provided by information providers are indicative in nature
Profile
|
Sanofi SA, formerly Sanofi-Aventis, is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients needs. Sanofi focuses on the field of healthcare with six growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets and animal health. Sanofi has a portfolio of prescription drugs, vaccines, generics and consumer healthcare products. In December 2011, Sanofi announced that it completed the divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International, Inc. The Company is active domestically and abroad, including other European countries, North and Latin Americas, Asia, Africa and Middle East. As of January 31, 2012, the Companys major shareholder was Loreal with a stake of 8.82%.
|
General information
-
Organization nameSanofi SA
-
Organization statusOperating organization
-
Site
-
IR Site
-
Previous organization nameSanofi-Aventis (to 05/05/2011)
News
-
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot11/09/2026
-
Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?26/08/2026
-
6 Undervalued Stocks That Crushed Earnings14/08/2026
-
Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks30/07/2026
-
Sanofi (NASDAQ: SNY) Prepares for Q2 2026 Earnings Report Amidst Strategic Shifts30/07/2026
IFRS/US GAAP reports
| 2026 | |
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
Show more
Hide
Authorization required
You need to request access
Stocks
General information
-
Organization nameSanofi SA
-
Organization statusOperating organization
-
Site
-
IR Site
-
Previous organization nameSanofi-Aventis (to 05/05/2011)
Codes
-
LEI549300E9PC51EN656011
-
SWIFTSAAVFRPPXXX
-
SIC2834 PHARMACEUTICAL PREPARATIONS
-
ICB4,500 Health Care
-
NACE*** ***
-
NAICS*** ***
-
CIK0001121404
-
EIN13-3529324
-
SIREN395030844
